Cargando…
Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD
The tumor immune microenvironment of lung cancer is associated with prognosis and immunotherapy efficacy. Long noncoding RNAs are identified as prognostic biomarkers associated with immune functions. We constructed a signature comprising differentially expressed immune-related lncRNAs to predict the...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436904/ https://www.ncbi.nlm.nih.gov/pubmed/34438369 http://dx.doi.org/10.18632/aging.203455 |
_version_ | 1783752070904414208 |
---|---|
author | Chen, Hang Shen, Wei Ni, Saiqi Sang, Menglu Wu, Shibo Mu, Yinyu Liu, Kaitai Li, Ni Zhu, Linwen Xu, Guodong |
author_facet | Chen, Hang Shen, Wei Ni, Saiqi Sang, Menglu Wu, Shibo Mu, Yinyu Liu, Kaitai Li, Ni Zhu, Linwen Xu, Guodong |
author_sort | Chen, Hang |
collection | PubMed |
description | The tumor immune microenvironment of lung cancer is associated with prognosis and immunotherapy efficacy. Long noncoding RNAs are identified as prognostic biomarkers associated with immune functions. We constructed a signature comprising differentially expressed immune-related lncRNAs to predict the prognosis of patients with lung adenocarcinoma. We established the immune-related lncRNA signature by pairing immune-related lncRNAs regardless of expression level and lung adenocarcinoma patients were divided into high- and low-risk groups. The prognosis of patients in the two groups was significantly different; The immune-related lncRNA signature could serve as an independent lung adenocarcinoma prognostic indicator. The signature correlated negatively with B cell, CD4+ T cell, M2 macrophage, neutrophil, and monocyte immune infiltration. Patients with low risk scores had a higher abundance of immune cells and stromal cells around the tumor. Gene set enrichment analysis showed that samples from low-risk group were more active in the IgA production in intestinal immune network and the T and B cell receptor signaling pathway. High-risk groups had significant involvement of the cell cycle, DNA replication, adherens junction, actin cytoskeleton regulation, pathways in cancer, and TGF-β signaling pathways. High risk scores correlated significantly negatively with high CTLA-4 and HAVCR2 expression and higher median inhibitory concentration of common anti-tumor chemotherapeutics (e.g., cisplatin, paclitaxel, gemcitabine) and targeted therapy (e.g., erlotinib and gefitinib). We identified a reliable immune-related lncRNA lung adenocarcinoma prognosis model, and the immune-related lncRNA signature showed promising clinical prediction value. |
format | Online Article Text |
id | pubmed-8436904 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Impact Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-84369042021-09-14 Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD Chen, Hang Shen, Wei Ni, Saiqi Sang, Menglu Wu, Shibo Mu, Yinyu Liu, Kaitai Li, Ni Zhu, Linwen Xu, Guodong Aging (Albany NY) Research Paper The tumor immune microenvironment of lung cancer is associated with prognosis and immunotherapy efficacy. Long noncoding RNAs are identified as prognostic biomarkers associated with immune functions. We constructed a signature comprising differentially expressed immune-related lncRNAs to predict the prognosis of patients with lung adenocarcinoma. We established the immune-related lncRNA signature by pairing immune-related lncRNAs regardless of expression level and lung adenocarcinoma patients were divided into high- and low-risk groups. The prognosis of patients in the two groups was significantly different; The immune-related lncRNA signature could serve as an independent lung adenocarcinoma prognostic indicator. The signature correlated negatively with B cell, CD4+ T cell, M2 macrophage, neutrophil, and monocyte immune infiltration. Patients with low risk scores had a higher abundance of immune cells and stromal cells around the tumor. Gene set enrichment analysis showed that samples from low-risk group were more active in the IgA production in intestinal immune network and the T and B cell receptor signaling pathway. High-risk groups had significant involvement of the cell cycle, DNA replication, adherens junction, actin cytoskeleton regulation, pathways in cancer, and TGF-β signaling pathways. High risk scores correlated significantly negatively with high CTLA-4 and HAVCR2 expression and higher median inhibitory concentration of common anti-tumor chemotherapeutics (e.g., cisplatin, paclitaxel, gemcitabine) and targeted therapy (e.g., erlotinib and gefitinib). We identified a reliable immune-related lncRNA lung adenocarcinoma prognosis model, and the immune-related lncRNA signature showed promising clinical prediction value. Impact Journals 2021-08-26 /pmc/articles/PMC8436904/ /pubmed/34438369 http://dx.doi.org/10.18632/aging.203455 Text en Copyright: © 2021 Chen et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Chen, Hang Shen, Wei Ni, Saiqi Sang, Menglu Wu, Shibo Mu, Yinyu Liu, Kaitai Li, Ni Zhu, Linwen Xu, Guodong Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD |
title | Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD |
title_full | Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD |
title_fullStr | Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD |
title_full_unstemmed | Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD |
title_short | Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD |
title_sort | construction of an immune-related lncrna signature as a novel prognosis biomarker for luad |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436904/ https://www.ncbi.nlm.nih.gov/pubmed/34438369 http://dx.doi.org/10.18632/aging.203455 |
work_keys_str_mv | AT chenhang constructionofanimmunerelatedlncrnasignatureasanovelprognosisbiomarkerforluad AT shenwei constructionofanimmunerelatedlncrnasignatureasanovelprognosisbiomarkerforluad AT nisaiqi constructionofanimmunerelatedlncrnasignatureasanovelprognosisbiomarkerforluad AT sangmenglu constructionofanimmunerelatedlncrnasignatureasanovelprognosisbiomarkerforluad AT wushibo constructionofanimmunerelatedlncrnasignatureasanovelprognosisbiomarkerforluad AT muyinyu constructionofanimmunerelatedlncrnasignatureasanovelprognosisbiomarkerforluad AT liukaitai constructionofanimmunerelatedlncrnasignatureasanovelprognosisbiomarkerforluad AT lini constructionofanimmunerelatedlncrnasignatureasanovelprognosisbiomarkerforluad AT zhulinwen constructionofanimmunerelatedlncrnasignatureasanovelprognosisbiomarkerforluad AT xuguodong constructionofanimmunerelatedlncrnasignatureasanovelprognosisbiomarkerforluad |